Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal

Lead Drug Felzartamab Is Pipeline-In-A-Product

 
• By Mandy Jackson
  
Isometric Business Success Concept. Entrepreneur business man leader. Searching for opportunities.
Biogen's HI-Bio buy merges immunology and rare disease capabilities • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business